The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding

被引:40
|
作者
Broome, MA
Hunter, T
机构
[1] SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA
[2] UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA
关键词
PDGF receptors; c-Src; SH3; domain; tyrosine phosphorylation;
D O I
10.1038/sj.onc.1200798
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Treatment of quiescent NIH3T3 cells with PDGF BE results in the transient activation and hyperphosphorylation of the protein-tyrosine kinase, c-Src. These effects correlate with novel serine and tyrosine phosphorylations in the N-terminal non-catalytic region of the molecule, which contains an SH3 and SH2 domain. In this study, a site of PDGF-induced tyrosine phosphorylation was mapped to Tyr 138 in the SH3 domain; Tyr 138 is exposed on the SH3 peptide binding surface. This same site is phosphorylated in vitro by the PDGF receptor when purified baculovirus-expressed c-Src is complexed with the activated receptor. Phosphorylation of Tyr 138 required association of c-Src with the PDGF receptor via its SH2 domain. When a c-Src Phe 138 mutant was stably expressed in Src(-) mouse fibroblasts, it was activated to the same extent as wild type c-Src following PDGF stimulation, indicating that phosphorylation of this site is not required for PDGF-mediated activation. However, Tyr 138 phosphorylation was found to diminish SH3 domain peptide ligand binding ability in vitro.
引用
收藏
页码:17 / 34
页数:18
相关论文
共 41 条
  • [1] The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding
    Martin A Broome
    Tony Hunter
    Oncogene, 1997, 14 : 17 - 34
  • [2] The role of backbone motions in ligand binding to the c-Src SH3 domain
    Wang, CY
    Pawley, NH
    Nicholson, LK
    JOURNAL OF MOLECULAR BIOLOGY, 2001, 313 (04) : 873 - 887
  • [3] Protein misfolding in chimeras of the sh3 domain of the c-src and fyn tyrosine kinase
    Plaza, Marina
    Carmen Salinas-Garcia, Ma
    Camara-Artigas, Ana
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : E185 - E185
  • [4] Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands
    Tiwari, Rakesh
    Brown, Alex
    Narramaneni, Seetha
    Sun, Gongqin
    Parang, Keykavous
    BIOCHIMIE, 2010, 92 (09) : 1153 - 1163
  • [5] SH3 domain of c-Src governs its dynamics at focal adhesions and the cell membrane
    Machiyama, Hiroaki
    Yamaguchi, Tomoyuki
    Sawada, Yasuhiro
    Watanabe, Tomonobu M.
    Fujita, Hideaki
    FEBS JOURNAL, 2015, 282 (20) : 4034 - 4055
  • [6] Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands
    Zhou, Peng
    Hou, Shasha
    Bai, Zhengya
    Li, Zhongyan
    Wang, Heyi
    Chen, Zheng
    Meng, Yang
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 (06) : 1122 - 1131
  • [7] CSK INHIBITION OF C-SRC ACTIVITY REQUIRES BOTH THE SH2 AND SH3 DOMAINS OF SRC
    SUPERTIFURGA, G
    FUMAGALLI, S
    KOEGL, M
    COURTNEIDGE, SA
    DRAETTA, G
    EMBO JOURNAL, 1993, 12 (07) : 2625 - 2634
  • [8] The effect of an engineered ATCUN motif on the structure and biophysical properties of the SH3 domain of c-Src tyrosine kinase
    Plaza-Garrido, Marina
    Carmen Salinas-Garcia, Ma
    Martinez, Jose C.
    Camara-Artigas, Ana
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2020, 25 (04): : 621 - 634
  • [9] 3D domain swapping in a chimeric c-Src SH3 domain takes place through two hinge loops
    Camara-Artigas, Ana
    Martinez-Rodriguez, Sergio
    Ortiz-Salmeron, Emilia
    Martin-Garcia, Jose M.
    JOURNAL OF STRUCTURAL BIOLOGY, 2014, 186 (01) : 195 - 203
  • [10] A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region
    Moroco, Jamie A.
    Baumgartner, Matthew P.
    Rust, Heather L.
    Choi, Hwan Geun
    Hur, Wooyoung
    Gray, Nathanael S.
    Camacho, Carlos J.
    Smithgall, Thomas E.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 86 (02) : 144 - 155